A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Birmingham

La Jolla

Orange

Redwood City

San Diego

Littleton

Glastonbury

Middletown

New Haven

Gainesville

Jacksonville

Miami

Naples

Weston

Winter Park

Decatur

Macon

Chicago

Indianapolis

Clive

Iowa City

Lexington

Louisville

Baton Rouge

New Orleans

Baltimore

Chevy Chase

Towson

Boston

Ann Arbor

Troy

Plymouth

Rochester

Lees Summit

Lebanon

Morristown

Great Neck

New York

Rochester

Asheville

Chapel Hill

Charlotte

Durham

Raleigh

Cincinnati

Cleveland

Oklahoma City

Portland

Pittsburgh

Germantown

Nashville

Grapevine

Houston

Plano

San Antonio

Salt Lake City

Burlington

Charlottesville

Richmond

Seattle

Tacoma

Madison

Adelaide

Brisbane

Fremantle

Herston

Malvern

Nambour

Graz

Salzburg

Vienna

Bonheiden

Brussels

Ghent

Leuven

Liège

Roeselare

Calgary

Edmonton

Vancouver

Brandon

Winnipeg

Halifax

Guelph

Kingston

London

Lévis

Montreal

Québec

Litoměřice

Prague

Bordeaux

Caen

Grenoble

Lille

Marseille

Nantes

Nice

Paris

Pessac

Rouen

Vandœuvre-lès-Nancy

Berlin

Erlangen

Hamburg

Hanover

Heidelberg

Herne

Kiel

Lÿneburg

Mannheim

München

Münster

Tübingen

Békéscsaba

Budapest

Debrecen

Pécs

Jerusalem

Petah Tikva

Tel Aviv

Almere Stad

Amsterdam

Amsterdam-Zuidoost

Leiden

Maastricht

Rotterdam

Auckland

Christchurch

Dunedin

Hamilton

Wellington

Lodz

Warsaw

Wroclaw

Cambridge

Cardiff

London

Manchester

Norwich

Nottinghamshirecc

Oxford